You don’t include chemo costs in the equation because that’s standard of care, pc patients be getting it anyway and should be covered by public purse, insurers etc. think of device as substitute for radiotherapy, an addition to chemo. Lot of chemo generic anyway.
ce mark requirements for marketing approval less than fda which (like drug) will need phase2/3 RCT evidence which OSL says it doing. Hence 40 showing safety and performance of device ok for Ce but not enough for US. Advantage earlier to market with CE and relevant to other countries outside Europe, better chance partner but you’re right that lower level evidence makes harder sell to doctors and reimbursement agencies, and therefore slower commercialisation trajectory. .
- Forums
- ASX - By Stock
- OSL
- Ann: Investor Update
Ann: Investor Update, page-47
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.2¢ |
Change
0.001(9.09%) |
Mkt cap ! $45.40M |
Open | High | Low | Value | Volume |
1.1¢ | 1.2¢ | 1.1¢ | $18.92K | 1.705M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
25 | 13619110 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 5063491 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
24 | 13469110 | 0.010 |
23 | 14339583 | 0.009 |
10 | 6887500 | 0.008 |
13 | 6339285 | 0.007 |
8 | 8595000 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 4158618 | 8 |
0.013 | 11108832 | 8 |
0.014 | 6187166 | 8 |
0.015 | 8500000 | 3 |
0.016 | 4766668 | 3 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online